Nóbrega Ana Caline, Rodrigues Bernardo, Torres Ana Catarina, Enzo Alfredo, Melo Ailton
Division of Neurology and Epidemiology, Federal University of Bahia, Brazil.
J Neurol Sci. 2007 Feb 15;253(1-2):85-7. doi: 10.1016/j.jns.2006.11.015. Epub 2007 Jan 16.
This study analysed if botulinum toxin type A (BTX-A) decreases drooling in 21 Parkinson's disease patients. BTX-A injections were given in the parotid glands. The severity of drooling decreased in 18 (86%) patients, while frequency was reduced in 8 (38%). In 11(52%) patients, the frequency of drooling remained constant, which may reflect more difficulties in swallowing, compared to the group that presented such improvement. Future trials assessing the level of swallowing dysfunction may be important to establish a prognosis for patients who keep the frequency of drooling in spite of decreased severity after BTX injection.
本研究分析了A型肉毒杆菌毒素（BTX-A）是否能减少21例帕金森病患者的流涎。BTX-A注射于腮腺。18例（86%）患者的流涎严重程度降低，8例（38%）患者的流涎频率降低。11例（52%）患者的流涎频率保持不变，与有改善的组相比，这可能反映出吞咽困难更大。未来评估吞咽功能障碍程度的试验对于为尽管注射BTX后流涎严重程度降低但流涎频率仍保持不变的患者建立预后可能很重要。
